Brendan Teehan
Known title: Chief Commercial OfficerCIK: 0001891900
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates. RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.
Transaction History
| PCRX | ▲ Buy | Grant | 51,714 | $0 | 2/11/2026 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 5,182 | $106K | 1/30/2026 | View on chart |
| PCRX | ▲ Buy | Grant | 402 | $4K | 12/31/2025 | View on chart |
| PCRX | ▲ Buy | Grant | 54,000 | $0 | 2/1/2025 | View on chart |
| ACAD | ▼ Sell | Open Market | 10,329 | $174K | 11/19/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 9,913 | — | 11/17/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 9,913 | — | 11/17/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 9,534 | $146K | 8/19/2024 | View on chart |
| ACAD | ▲ Buy | Grant | 5,024 | $0 | 8/16/2024 | View on chart |
| ACAD | ▲ Buy | Grant | 13,629 | $0 | 8/16/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 3,477 | $59K | 5/2/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,814 | — | 5/1/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 2,568 | $46K | 4/8/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 5,024 | — | 4/5/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 5,140 | $92K | 3/27/2024 | View on chart |
| ACAD | ▲ Buy | Grant | 10,048 | $0 | 3/25/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 624 | $15K | 2/26/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,107 | — | 2/23/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 731 | $22K | 1/8/2024 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,287 | — | 1/6/2024 | View on chart |
| ACAD | ▼ Sell | Open Market | 4,960 | $112K | 11/20/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 4,956 | — | 11/17/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 4,956 | — | 11/17/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 14,869 | — | 5/17/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 14,869 | $335K | 5/17/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 14,869 | — | 5/17/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 548 | $12K | 5/1/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,567 | $0 | 4/29/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,751 | $32K | 4/6/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 5,024 | — | 4/5/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 461 | $9K | 2/24/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,107 | — | 2/23/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 532 | $9K | 1/9/2023 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,286 | — | 1/6/2023 | View on chart |
| ACAD | ▼ Sell | Open Market | 552 | $10K | 5/2/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,567 | — | 4/29/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,106 | $0 | 2/23/2022 | View on chart |
| ACAD | ▼ Sell | Open Market | 472 | $11K | 2/23/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 1,286 | — | 1/6/2022 | View on chart |
| ACAD | ▼ Sell | Open Market | 538 | $12K | 1/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.